for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Misonix Inc

MSON.OQ

Latest Trade

11.11USD

Change

0.00(-0.00%)

Volume

40,852

Today's Range

11.07

 - 

11.71

52 Week Range

6.71

 - 

22.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.11
Open
11.35
Volume
40,852
3M AVG Volume
1.84
Today's High
11.71
Today's Low
11.07
52 Week High
22.11
52 Week Low
6.71
Shares Out (MIL)
17.37
Market Cap (MIL)
197.54
Forward P/E
-22.61
Dividend (Yield %)
--

Latest Developments

More

Misonix Reports Q4 Loss Per Share $0.50

Misonix Reports Q4 Revenue $13.5 Mln Vs $9.8 Mln

Misonix Reports Q2 Loss Per Share $0.33

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Misonix Inc

Misonix, Inc. (Misonix) is a medical devices company. Misonix is engaged in designing, manufacturing and marketing of minimally invasive therapeutic ultrasonic medical devices. Its products include BoneScalpel Surgical System (BoneScalpel), SonicOne Wound Cleansing and Debridement System (SonicOne) and SonaStar Surgical Aspirator (SonaStar). BoneScalpel is used for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue. SonaStar is used to emulsify and remove soft and hard tumors, primarily in the neuro and general surgery field. SonicOne offers tissue specific debridement and cleansing of wounds and burns for effective removal of devitalized tissue and fibrin deposits while sparing viable cells. Its nexus, which is its ultrasonic surgical platform that combines the features of BoneScalpel, SonaStar and SonicOne into a single full integrated platform, powered by its digital algorithm.

Industry

Medical Equipment & Supplies

Contact Info

1938 New Hwy

FARMINGDALE, NY

11735-1204

United States

+1.631.9279113

https://misonix.com/

Executive Leadership

Paul A. LaViolette

Independent Chairman of the Board

Stavros G. Vizirgianakis

President, Chief Executive Officer, Director

Charles Miner

Independent Director

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-0.850

2019

-0.790

2020

-1.190

2021(E)

-0.617
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.16
Price To Book (MRQ)
1.35
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
29.80
LT Debt To Equity (MRQ)
26.32
Return on Investment (TTM)
-16.70
Return on Equity (TTM)
-14.90

Latest News

Latest News

BRIEF-Misonix Reports Q4 Revenue $13.5 Mln Vs $9.8 Mln

* MISONIX REPORTS PRELIMINARY FISCAL 2020 FOURTH QUARTER REVENUE OF APPROXIMATELY $13.5 MILLION

BRIEF-Misonix Says Unit Entered Into Second Amendment To Their Existing Credit Agreement With SWK Funding LLC

* MISONIX INC - ON JUNE 30, CO, UNIT ENTERED INTO SECOND AMENDMENT TO THEIR EXISTING CREDIT AGREEMENT WITH SWK FUNDING LLC

BRIEF-Misonix Inc Applied For $5.2 Mln Loan Under Paycheck Protection Program

* MISONIX INC - APPLIED FOR UNSECURED $5.2 MILLION LOAN UNDER PAYCHECK PROTECTION PROGRAM

BRIEF-Misonix Qtrly Earnings Per Share $0.23

* REMAIN CONFIDENT IN ABILITY TO END FISCAL 2018 WITH DOUBLE-DIGIT TOP-LINE GROWTH AND TO CONTINUE THAT GROWTH TREND INTO FISCAL 2019

BRIEF-Misonix Files For Mixed Shelf Offering Of Up To $75 Mln

* MISONIX INC FILES FOR MIXED SHELF OFFERING OF UP TO $75 MILLION - SEC FILING Source text: (https://bit.ly/2IPdoTd) Further company coverage:

BRIEF-Misonix Q2 Revenue $8.3 Million Versus $6.0 Million

* MISONIX INC - QTRLY REVENUE $8.3 MILLION VERSUS $6.0 MILLION

BRIEF-Misonix reports first quarter financial results

* Misonix reports first quarter fiscal year 2018 financial results

BRIEF-Misonix Inc's revenue for Q1 was $7.3 mln

* Misonix Inc - revenue for Q1 was $7.3 million, an increase of 18pct compared with $6.2 million in the previous year’s first quarter

BRIEF-MISONIX ENTERS INTO $11 MILLION LICENSE, ROYALTY AND MANUFACTURING AGREEMENT

* MISONIX INC - ENTERED INTO A LICENSE AND EXCLUSIVE MANUFACTURING AGREEMENT WITH HUNAN XING HANG RUI KANG BIO-TECHNOLOGIES CO LTD.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up